Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Arthritis, Rheumatoid 2Myasthenia Gravis 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Glioblastoma 1

Interventions

Cyclophosphamide 41Peripheral Blood Stem Cell Transplantation 40fludarabine phosphate 36Whole-Body Irradiation 27Mycophenolic Acid 27Tacrolimus 23Busulfan 23Cyclosporine 22Antilymphocyte Serum 20Etoposide 17Methotrexate 16Filgrastim 16Melphalan 14romidepsin 13Radiotherapy 13Flow Cytometry 12Methylprednisolone 10Brentuximab Vedotin 10Therapeutics 9Psychiatric Rehabilitation 9Lenalidomide 8pembrolizumab 7fludarabine 7Sirolimus 7Rituximab 7Bortezomib 7Bexarotene 7mogamulizumab 6Polymerase Chain Reaction 6Gemcitabine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, T-Cell, Cutaneous × tofacitinib × Clear all
NCT06698822 2026-04-14

A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA

M.D. Anderson Cancer Center

Phase 2 Recruiting
20 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡